4 Drugs Stocks Nudging The Industry Higher

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 11 points (0.1%) at 15,533 as of Tuesday, July 30, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 1,505 issues advancing vs. 1,392 declining with 116 unchanged.

The Drugs industry currently sits up 0.6% versus the S&P 500, which is up 0.2%. Top gainers within the industry include Celgene Corporation ( CELG), up 1.6%, Pfizer ( PFE), up 0.6% and Amgen ( AMGN), up 0.8%. A company within the industry that fell today was Bristol-Myers Squibb Company ( BMY), up 0.7%.

TheStreet would like to highlight 4 stocks pushing the industry higher today:

4. Sanofi ( SNY) is one of the companies pushing the Drugs industry higher today. As of noon trading, Sanofi is up $0.39 (0.7%) to $52.97 on light volume. Thus far, 350,839 shares of Sanofi exchanged hands as compared to its average daily volume of 1.1 million shares. The stock has ranged in price between $52.92-$53.45 after having opened the day at $53.35 as compared to the previous trading day's close of $52.58.

Sanofi researches, develops, manufactures, and markets healthcare products worldwide. The company operates through Pharmaceuticals, Human Vaccines, and Animal Health segments. Sanofi has a market cap of $142.2 billion and is part of the health care sector. Shares are up 11.9% year to date as of the close of trading on Monday. Currently there are 6 analysts that rate Sanofi a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Sanofi as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Sanofi Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Vertex Pharmaceuticals ( VRTX) is up $3.00 (3.8%) to $82.66 on heavy volume. Thus far, 2.3 million shares of Vertex Pharmaceuticals exchanged hands as compared to its average daily volume of 1.8 million shares. The stock has ranged in price between $81.00-$85.72 after having opened the day at $81.49 as compared to the previous trading day's close of $79.66.

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. Vertex Pharmaceuticals has a market cap of $17.9 billion and is part of the health care sector. Shares are up 92.6% year to date as of the close of trading on Monday. Currently there are 12 analysts that rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Vertex Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full Vertex Pharmaceuticals Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Herbalife ( HLF) is up $2.93 (4.8%) to $63.50 on heavy volume. Thus far, 10.0 million shares of Herbalife exchanged hands as compared to its average daily volume of 2.7 million shares. The stock has ranged in price between $61.73-$66.23 after having opened the day at $64.60 as compared to the previous trading day's close of $60.57.

Herbalife Ltd., a network marketing company, sells weight management, healthy meals and snacks, sports and fitness, energy and targeted nutritional products, and personal care products worldwide. Herbalife has a market cap of $6.0 billion and is part of the consumer goods sector. Shares are up 77.4% year to date as of the close of trading on Monday. Currently there are 6 analysts that rate Herbalife a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Herbalife as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, expanding profit margins, good cash flow from operations and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Herbalife Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Regeneron Pharmaceuticals ( REGN) is up $5.64 (2.1%) to $274.84 on light volume. Thus far, 205,011 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $268.71-$276.51 after having opened the day at $270.41 as compared to the previous trading day's close of $269.20.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $25.8 billion and is part of the health care sector. Shares are up 57.4% year to date as of the close of trading on Monday. Currently there are 10 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and compelling growth in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Regeneron Pharmaceuticals Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 4 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).
null

If you liked this article you might like

Citi Will Refund $335 Million in Card Charges: LIVE MARKETS BLOG

Citi Will Refund $335 Million in Card Charges: LIVE MARKETS BLOG

Generic Drug Makers Hurt By Latest Federal Government Budget

Generic Drug Makers Hurt By Latest Federal Government Budget

Stock Market Drop Not Seen Dampening Healthcare Deal Activity

Stock Market Drop Not Seen Dampening Healthcare Deal Activity

Investors Are Trying to Figure Out the 'Powell Put'

Investors Are Trying to Figure Out the 'Powell Put'

Sanofi Announces Second Billion-Dollar Deal In a Week, and It May Not Be Done

Sanofi Announces Second Billion-Dollar Deal In a Week, and It May Not Be Done